Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17191962 | 0.90 | MRGPRX4 (0.58) | MRGPRX4PTGER1MEN1KMT2ABRD4 | |
| SCHEMBL11762649 | 0.90 | RXRA (0.61) | RXRAMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL1056260 | 0.90 | HPGD (0.61) | RXRAMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL2291970 | 0.89 | MRGPRX4 (0.57) | RXRAMRGPRX4PTGER1MEN1KMT2A | |
| SCHEMBL7168025 | 0.87 | RXRA (0.62) | RXRAMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL30102546 | 0.87 | RXRA (0.62) | RXRAMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL15673277 | 0.85 | RXRA (0.62) | RXRAMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL14699807 | 0.84 | RAB9A (0.58) | RXRAMRGPRX4PTGER1NPC1RAB9A | |
| SCHEMBL15969027 | 0.84 | MEN1 (0.63) | MRGPRX4PTGER1MEN1KMT2AHPGD | |
| SCHEMBL1936167 | 0.83 | MRGPRX4 (0.57) | RXRAMRGPRX4PTGER1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2011-05-05 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | RXRA 3906/4885MRGPRX4 3366/4885PTGER1 4307/4885 |
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | RXRA 3731/4885MRGPRX4 3162/4885PTGER1 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.